[{"orgOrder":0,"company":"St. Jude Children","sponsor":"Medicines for Malaria Venture | Eisai Inc | GHIT Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SJ733","moa":"PfATP4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ Medicines for Malaria Venture | Eisai Inc | GHIT Fund","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ Medicines for Malaria Venture | Eisai Inc | GHIT Fund"},{"orgOrder":0,"company":"Eisai","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"SJ733","moa":"PfATP4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eisai","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ GHIT Fund","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ GHIT Fund"},{"orgOrder":0,"company":"R. Kiplin Guy","sponsor":"GHIT Fund | Eisai Inc | Asociacion Civil Selva Amazonica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SJ733","moa":"PfATP4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"R. Kiplin Guy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"R. Kiplin Guy \/ GHIT Fund | Eisai Inc | Asociacion Civil Selva Amazonica","highestDevelopmentStatusID":"8","companyTruncated":"R. Kiplin Guy \/ GHIT Fund | Eisai Inc | Asociacion Civil Selva Amazonica"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Undisclosed"}]